Navigation Links
Data Presented at ACR Meeting Demonstrate Safety of Colcrys® (Colchicine, USP) for Treatment of Gout Flares in Patients with Multiple Co-Morbid Conditions
Date:11/8/2010

ATLANTA, Nov. 8, 2010 /PRNewswire/ -- Patients who experience gout flares can be treated safely with Colcrys® (colchicine, USP), even in the presence of co-morbid conditions that often present physicians with treatment challenges, according to a new analysis presented here at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

"Many patients with gout have other serious health conditions to consider, including cardiovascular and metabolic disorders, hypertension and kidney disease, which can make gout treatment complex," said Matthew W. Davis, M.D., R.Ph., Chief Medical Officer, URL Pharma. "This analysis demonstrates that patients with these comorbidities did not have an increased likelihood of adverse events from the use of Colcrys."

Data were collected as part of a post-hoc analysis of The Acute Gout Flare Receiving Colchicine Evaluation (AGREE) trial, a pivotal Phase 3 study of Colcrys in the treatment of gout flares. AGREE results were presented at the 2009 ACR annual meeting, and were published in Arthritis & Rheumatism in March 2010.

Colcrys is the only single-ingredient colchicine product approved by the U.S. Food and Drug Administration (FDA) for the prevention and treatment of gout flares, and for the treatment of Familial Mediterranean Fever (FMF).

Study Design

This Phase 3, randomized, double-blind, placebo-controlled parallel group study represents a regression analysis of the previously presented AGREE trial. A total of 185 patients meeting ACR criteria for acute gout flares were randomized to receive, within 12 hours of symptom onset, either high-dose colchicine (1.2 mg, then 0.6 mg hourly x 6 hours = 4.8 mg total); Colcrys (1.2 mg, then 0.6 mg in 1 hour = 1.8 mg total, followed by 5 placebo doses hourly); or placebo (2 capsules, then 1 capsule hourly x 6 hours).  

Logistics regression was undertaken using presence or absence of adverse events (AEs
'/>"/>

SOURCE URL Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW ... for operable and inoperable solid tumor cancers, announced today that ... th Annual Phacilitate Immunotherapy Forum in Washington ... will take place on January 26 at 10:30 a.m. EST ...
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced ... for the compounding, packaging and distributing of its naltrexone tablets. ... the United States . KRS Global ... naltrexone tablets in various strengths for individual patients in response ...
(Date:1/23/2015)... 23, 2015  HyGreen, Inc., a leader in hand hygiene ... RCA Medical, a subsidiary of Ascendis Health Limited, in ... Each year, hundreds of millions of patients around the ... are transmitted from patient to patient via the unwashed ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... 2011 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... and developing breakthrough treatments for human disease, today updated ... the three months ended March 31, 2011.   ... significant progress.  Results from a mechanistic study of a ...
... DBI announced today that they assisted PartsSource, Inc., ... replacement parts and software solutions for clinical engineers, ... Oracle database to the IBM DB2 for LUW ... customers with improved performance when ordering parts online, ...
Cached Medicine Technology:Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results 2Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results 3Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results 4Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results 5Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results 6PartsSource Selects DBI as DB2 Performance Tool Vendor of Choice 2
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... provide relief for "tennis elbow" but needs to be ... article in CMAJ ( Canadian Medical Association ... The study, a randomized controlled trial of 48 patients, ... the Tehran University of Medical Sciences that serves patients ...
... HACKENSACK, N.J. (April 26, 2010, 4 p.m. EDT) Myelodysplastic syndromes ... are nearly five times more common in seniors than previously ... John Theurer Cancer Center at Hackensack University Medical Center. ... patients are at much higher risk for heart attack, diabetes ...
... to be good candidates upon death, study finds , ... developed a new tool that may help neurologists identify ... that could potentially boost organ donation rates. , Coma ... for organ donation when they die because their other ...
... high cholesterol or diabetes now widespread, CDC survey finds ... of all American adults have either high blood pressure, ... for heart disease, stroke and other cardiovascular problems, a ... the U.S. National Health and Nutrition Examination Survey (NHANES) ...
... - The American Society of Pediatric Otolaryngology (ASPO) will ... during the 2010 Combined Otolaryngology Spring Meetings (COSM) - ... Vegas, NV. During the ASPO meeting, hundreds ... sessions featuring expert panelists will be presented focusing on ...
... ... book on both sides of the Atlantic. This layman,s account of his interest and research ... self worth, regardless of historical, cultural or religious backgrounds, as it strives to touch all ... Washington, ...
Cached Medicine News:Health News:Botulinum injection provides relief of tennis elbow 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 3Health News:Test Spots Potential Organ Donors Among Coma Patients 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 3Health News:Scientific meeting will host new research in children's ear, nose and throat health 2Health News:Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15 2
CMF OL1000 Bone Growth Stimulators are portable, battery-powered medical devices indicated for use in the noninvasive treatment of an established nonunion fracture acquired secondary to trauma, exclu...
... A surgically implanted bone growth stimulator for ... OsteoGen surgically implanted bone growth stimulator is ... nonunions when surgery is already planned or ... Because the OsteoGen is totally surgically implanted, ...
... proud to offer one of ... market at only 188 grams! ... a superior flow rate with ... mechanisms. The complementing electrodes provide ...
... Cryocare® CS is a ... and treatment system designed ... allow unlimited flexibility. Cryocare ... meet specific physician needs ...
Medicine Products: